Dose Escalation of Bivatuzumab Mertansine in Patients With Advanced Squamous Cell Carcinoma of the Head and Neck or Esophagus
Condition(s):Carcinoma, Squamous CellLast Updated:October 1, 2014Terminated
Hide Studies Not Open or Pending
Condition(s):Carcinoma, Squamous CellLast Updated:October 1, 2014Terminated
Condition(s):Carcinoma, Squamous CellLast Updated:February 9, 2016Completed
Condition(s):Carcinoma, Squamous CellLast Updated:May 30, 2012Withdrawn
Condition(s):Squamous Cell Carcinoma of Skin; Carcinoma, Squamous CellLast Updated:October 7, 2022Completed
Condition(s):Carcinoma, Squamous Cell; Carcinoma, Squamous Cell of Head and NeckLast Updated:November 3, 2021Terminated
Condition(s):Oral Squamous Cell CarcinomaLast Updated:April 20, 2023Completed
Condition(s):Cutaneous Squamous Cell CarcinomaLast Updated:March 22, 2024Recruiting
Condition(s):Squamous Cell Carcinoma of the Head and Neck; Squamous Cell CarcinomaLast Updated:January 13, 2022Terminated
Condition(s):Esophageal Squamous Cell CarcinomaLast Updated:March 4, 2024Terminated
Condition(s):Oral Squamous Cell CarcinomaLast Updated:September 13, 2023Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.